FindTrial
Sign In

Effect of ayurveda drug Jatamansi in patients suffering from depression

Investigating the Effects of Ayurvedic Anti-Depressant Drug (Nardostachys Jatamansi DC.) Complementing Allopathic Medication in Patients with Major Depressive Disorder (Vishada)

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2021/01/030417
Enrollment
60
Registered
2021-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F321- Major depressive disorder, singleepisode, moderate

Interventions

Intervention1: Nardostachys jatamansi: Group A- Nardostachys jatamansi 3g trice daily with one glass of milk with allopathic antidepressant escitalopram 10-20 mg Control Intervention1: Allopathic anti

Sponsors

Central Council for Research in Ayurveda Science
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients of Vishada according to Ayurveda parameters and Major Depressive Disorder as per ICD-10: moderate depression (HDRS scores of 17-23), prescribed with Escitalopram 10-20mg for Subjects of either gender in the age group of 18 to 45 years Patients willing to participate in the study and give informed written consent

Exclusion criteria

Exclusion criteria: Patients suffering from any other known cardiorespiratory, neurological or endocrinological, systemic disorders as assessed by history and detailed clinical examination Patients suffering from other psychiatric disorders: alcohol/substance abuse, psychotic features (Anya manovaha sroto vikara), suicidal tendency (Na prana Akanksha) Female patients who are pregnant or lactating (Garbhini and Soothika) Depression with suicidal tendency/ thoughts Other psychotic disorders Cardiovascular disorders Patients with contraindications for TMS (Transcranial magnetic stimulation): Major head injury, epilepsy, metallic implants anywhere in the body Patients who have completed participation in any other clinical trial during the past six (06) months and any other condition which the Investigators think may jeopardize the study

Design outcomes

Primary

MeasureTime frame
Hamilton depression rating scaleTimepoint: Baseline, 28th day, 56th day, 84th day—

Secondary

MeasureTime frame
Heart rate variability Transcranial magnetic stimulation Plasm Brain derived neurotrophic factor Serum glutamate receptor antibodiesTimepoint: Baseline, 56th day—

Countries

India

Contacts

Public ContactKishore Kumar R

NIMHANS

kaviudupa@gmail.com9844497111

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026